Integra LifeSciences Inc. (IART) Enterprise Value to EBITDA Ratio
The historical EV/EBITDA chart for Integra LifeSciences (IART) visualizes the link between market value and its strategy of neurosurgery dominance through the sale of Codman consumables. Manufacturing capacities in Europe and the US ensure the stable production of complex implants. The value of 8.13 represents the current metric level, confirming business resilience due to the deep integration of brands into clinics, which protects the company from competitors.
Comprehensive metric breakdowns and analytics for integralife.com (IART)
- current price and projected stock value:
- market capitalization details:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Integra LifeSciences|IART - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Integra LifeSciences Holdings Corporation|IART - Company Total Debt|Debts to Book Capitalization Integra LifeSciences Inc.|IART - Long-Term Debt|Company Short-Term Debts Integra LifeSciences|Quick Ratio integralife.com
- financial results and valuation multiples details:
IART - Net Financial Result|Projected Future Earnings Integra LifeSciences|IART - Price to Earnings Ratio|Forward P/E Multiple Integra LifeSciences|IART - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Integra LifeSciences Inc.|IART - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Integra LifeSciences|IART - Earnings per share for the trailing year|Quarterly EPS earnings growth integralife.com|IART - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Integra LifeSciences
Analysis of all company metrics:Integra IART
For Integra LifeSciences (IART), the ratio of enterprise value to operating profit reflects capitalization resilience inclusive of debt amid margin volatility in the neurosurgery segment and product recall risks. By analyzing the business valuation via the EV/EBITDA multiple, an investor determines how efficiently assets generate income relative to total liabilities, which is critical when assessing the success of new biomaterials and FDA approvals.
Competitor analysis
EV/EBITDA Multiple BSX (Boston Scientific Inc)|Total Company Value to Operating Income Before Depreciation Ratio Edwards Lifesciences Inc. (EW)|RMD: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio PODD|ZBH: EV/EBITDA Multiple|Company Value to EBITDA The Cooper Companies, Inc. (COO)|ALGN (Align Technology Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation GMED (NuVasive)|Enterprise Value to EBITDA Ratio TMDX (TransMedics)|ATEC (atecspine.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artivion AORT|ENOV - Enterprise Value to EBITDA Ratio|Motiva - EV/EBITDA Multiple|Company Value to EBITDA iLet Bionic Pancreas|IRMD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation EMBC|TNDM (Tandem Diabetes Care, Inc.) - EV/EBITDA Multiple|AxoGen Inc (AXGN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple SIBN|Enterprise Value to EBITDA Ratio Orthofix Corp OFIX|EV/EBITDA Multiple BVS (Bioventus Inc.)|EV/EBITDA Multiple OrthoPediatrics Corp KIDS|TMCI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRTA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CARL (Carlsmed Corp) - Enterprise Value to EBITDA Ratio|RxSight Ophthalmic - Business Value to Operating Income Before Depreciation|CLPT (ClearPoint Neuro Inc.) - EV/EBITDA Multiple|Company Value to EBITDA stereotaxis.com STXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neuronetics (STIM)|Sight Sciences Inc. (SGHT) - Enterprise Value to EBITDA Multiple|Orchestra BioMed - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Anika Therapeutics Inc. ANIK|InspireMD, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Jin Medical International ZJYL|vivani.com (VANI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio XTNT (Xtant Medical)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroOne Corp|Enterprise Value to EBITDA Ratio Modular Med (MODD)|EV/EBITDA Multiple MYO|COCH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vivos Therapeutics, Inc. VVOS|NVNO: Enterprise Value to Operating Income Before Depreciation|SINT: Enterprise Value to EBITDA Ratio|Tenon Medical Inc - Enterprise Value to Operating Income Before Depreciation Ratio|LFWD: EV/EBITDA Multiple|AMIX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INVO Fertility|Enterprise Value to Operating Income Before Depreciation BBLG (Bone Biologics Corp.)|Enterprise Value to EBITDA Ratio AXNX (Axonics Modulation Technologies)|Enterprise Value to Operating Income Before Depreciation Ratio BIOL|EV/EBITDA Multiple DYNT (Dynatronics)|Paragon 28 Inc. (FNA) - Company Value to EBITDA|INVO Bio - EV/EBITDA Multiple
